PsilOCD: A Pharmacological-Challenge Feasibility Study
NCT06258031
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
19
Enrollment
OTHER
Sponsor class
Conditions
Obsessive-Compulsive Disorder
Interventions
DRUG:
Psilocybin (COMP360)
Sponsor
Imperial College London